Skip to main content

Decision Support & Provider Education

Our decision support services are designed to present patient results in the clearest way possible and to provide information to help you establish a treatment plan. From interpretation of results on each report to expert consultations, we can help you make the most of comprehensive genomic profiling (CGP) in your practice.

Streamlined Reports and Result Interpretation

Streamlined Reports

Simplified test results provide information about genomic findings and biomarkers and their associated targeted therapies when available. We also provide information on clinically relevant alterations and available clinical trial options specific to each patient’s cancer. In addition to streamlined reports, other benefits include:

  • A single partner for all your testing services means consistent reporting for the comparison of results across the patient journey  

  • Reports for FoundationOne Liquid CDx include historic patient findings from earlier FoundationOne tests, which allow you to follow your patients’ genomic profiles across the duration of their diseases

FoundationOne®CDx and FoundationOne®Liquid CDx Report Features

1

FDA-Approved Therapies

Reports include a list of FDA-approved companion diagnostics, if available, to identify patients who may be eligible for treatment with associated therapies

2

Potential Resistance

This section appears when patients may be resistant to therapy based on their genomic profile

Illustration of a Foundation Medicine report

3

All Other Biomarkers

All other biomarkers and genomic signatures, including TMB and MSI,* without companion diagnostic claims

4

Laboratory Professional Services

Interpretive content that can be used for patient management in accordance with professional guidelines in oncology

Medical Inquiries: Result Interpretation

Discuss patient results with the Medical Affairs team at Foundation Medicine. This robust on-call program is covered by internal experts such as the Medical Science Liaison (MSL) team or by internal and external oncologists who are subject matter experts and consultants for Foundation Medicine.

  • Inquiries can be escalated via phone, email, or through the “Ask an Expert” portal 

  • Our team responds to over 200 inquiries per month

  • Inquiries are handled within 24-48 hours in 95% of cases

We’re Here to Help

Questions? Our Client Services team is on hand to help.

Contact Us

Additional Notes

*On FoundationOne Liquid CDx, MSI status will be reported for samples determined to have high microsatellite instability as a laboratory professional service which is not reviewed or approved by the FDA.

As of May 2021

Important Safety Information

Select

FoundationOne CDx

FoundationOne®CDx is a qualitative next-generation sequencing based in vitro diagnostic test for advanced cancer patients with solid tumors and is for prescription use only. The test analyzes 324 genes as well as genomic signatures including microsatellite instability (MSI) and tumor mutational burden (TMB) and is a companion diagnostic to identify patients who may benefit from treatment with specific therapies in accordance with the approved therapeutic product labeling. Additional genomic findings may be reported and are not prescriptive or conclusive for labeled use of any specific therapeutic product. Use of the test does not guarantee a patient will be matched to a treatment. A negative result does not rule out the presence of an alteration. Some patients may require a biopsy. For the complete label, including companion diagnostic indications and important risk information, please visit www.F1CDxLabel.com. 

FoundationOne Liquid CDx

FoundationOne®Liquid CDx is for prescription use only and is a qualitative next-generation sequencing based in vitro diagnostic test for advanced cancer patients with solid tumors. The test analyzes 324 genes utilizing circulating cell-free DNA and is FDA-approved to report short variants in 311 genes and as a companion diagnostic to identify patients who may benefit from treatment with specific therapies (listed in Table 1 of the Intended Use) in accordance with the approved therapeutic product labeling. Additional genomic findings may be reported and are not prescriptive or conclusive for labeled use of any specific therapeutic product. Use of the test does not guarantee a patient will be matched to a treatment. A negative result does not rule out the presence of an alteration. Patients who are negative for companion diagnostic mutations should be reflexed to tumor tissue testing and mutation status confirmed using an FDA-approved tumor tissue test, if feasible. For the complete label, including companion diagnostic indications and complete risk information, please visit www.F1LCDxLabel.com.